ADAM17 recombinant pro-domain has been shown to specifically inhibit ADAM17 in different mouse models [8,126,127,128] and might enter into clinical development for the treatment of inflammatory bowel disease [118]. Here, ADAM17 is linked to inflammatory bowel disease.